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We welcome the literature review by Bracchi and colleagues[1] describing potential drug-drug interactions 
(DDIs) between antiretrovirals (ART) and recreational drugs. Data on potential DDIs are important for HIV 
clinical management, but remain scarce. We have previously published results from the UK observational 
Antriretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study (2011/12), in which half of the 2,248 
HIV-diagnosed men who have sex with men (MSM) surveyed had used a recreational drug in the previous 
three months, with 24% using three or more drugs during the same period.[2] Linkage of routine clinical HIV 
records with the ASTRA questionnaire in a large subset of participants allows for examination of the 
prevalence of recreational drug use according to ART regimen used. To our knowledge there are no existing 
data on concurrent use of recreational drugs and ART among HIV-diagnosed MSM outpatients in the UK.  
The primary mechanism of ART elimination is mediated through the hepatic cytochrome p450 (CYP) complex 
of proteins. This pathway is also shared by recreational drugs, which can either induce CYP activity, leading to 
decrease of ART concentration to sub-therapeutic levels, or inhibit it, resulting in toxic drug accumulation.[3] 
Bracchi et al suggest the potential for harm arising from DDIs is highest between recreational drugs and 
ritonavir or cobicistat-boosted protease inhibitors (PI/r), and to a lesser extent between recreational drugs and 
non-nucleoside reverse transcriptase inhibitors (NNRTI). The potential for interaction is lowest with Nucleoside 
Reverse Transcriptase Inhibitors, maraviroc (C-C chemokine receptor type 5 antagonist), raltegravir and 
dolutegravir (integrase inhibitors), and rilpivirine (NNRTI). Specifically, PI/r have highest interaction potential 
with benzodiazepines, erectile dysfunction drugs (EDDs), and ketamine, moderate with crystal 
methamphetamine, methylenedioxymethamphetamine (MDMA), and mephedrone, and lowest interaction 
potential with cocaine. NNRTIs (efavirenz, nevirapine, etravirine) also have the potential to interact with 
cocaine. Although there is low potential for interaction between cannabis, alcohol, nitrites, and ART, when 
taken with γ-Hydroxybutyric acid (GHB), ethanol enhances the sedative and respiratory depressant effects of 
GHB.[4] The interaction between GHB and ritonavir, NRTIs, or NNRTIs, remains unclear.   
We therefore examined the prevalence of recreational drug use in the three months prior to ASTRA 
questionnaire completion according to ART regimen among HIV-diagnosed MSM on ART. A hierarchical 
variable was created to reflect on degree of DDI from high to low, for MSM on; (i.) ritonavir or cobicistat-
boosted PIs (regardless of other drugs included in the regimen), (ii.)  efavirenz or nevirapine (but not on 
ritonavir-boosted PIs), and (iii.) other regimens (excluding ritonavir or efavirenz/nevirapine but including 
rilpivirine, raltegravir, dolutegravir, or maraviroc based regimens and emtricitabine/tenofovir/etravirine or 
atazanavir/lamivudine/abacavir combinations). Among 2,248 MSM, 2,117 (94.2%) consented to linkage with 
clinic data; linked data on ART history is currently available from 4 out of 8 participating clinics for 1,325 
(58.9%) MSM, of whom 1,167 (88.1%) reported being on ART at the time of the questionnaire and had a 
clinical record of being on ART for at least three months prior to ASTRA completion. Thus findings reported are 
based on 1,167 MSM, of whom 624 (53.5%) were on a regimen including a PI/r, 523 (44.8%) on efavirenz or 
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nevirapine but not PI/r and 20 (1.7%) were on other regimens only (Table 1).  Among 1,167 MSM, 613 (52.5%) 
had used recreational drugs in the previous three months, of whom 295 (25.3%) had used 3 or more drugs.  
The overall prevalence of recreational drug use was similar across regimens, with over 50% of MSM on each 
regimen having used recreational drugs in the previous three months. (Table 1)  Prevalence of polydrug use 
was similar for MSM on PI/r regimens and those on efavirenz or nevirapine (26.8 vs 23.3% used ≥3 drugs). The 
prevalence of specific drugs comparing PI/r and efavirenz or nevirapine regimens (according to range of DDI 
potential with ritonavir from high to low) was: EDDs ritonavir 24.2% vs. efavirenz  or nevirapine 19.7%; 
ketamine 11.1 vs. 12.6%, chemsex drugs 16.7 vs 15.1%, and MDMA 10.7% for both regimen types. 
Additionally, among MSM on efavirenz or nevirapine, 22.0% used cocaine, and 9.6% used GHB. Higher alcohol 
consumption (WHO-AUDIT modified questionnaire score ≥6) was prevalent in 14.7% of those on PI/r and 
16.8% of those on efavirenz or nevirapine. Among 180 MSM with higher alcohol consumption, 61.1% (n=110) 
had used recreational drugs in the previous three months, of whom 32.2% (n=58) used 3 or more drugs; of 
those, 56.9% (n=33) were on PI/r and 43.1% (n=25) were on efavirenz or nevirapine regimens.   
In summary, recreational drug use and polydrug use are common among HIV-positive MSM receiving 
treatment in the UK, and similarly distributed across both PI/r and NNRTI regimens. This suggests that drug use 
may not be considered the most important issue by clinicians when deciding on an appropriate ART regimen 
and that competing concerns, such as choice of regimen most forgiving to periods of non-adherence, may be 
given higher priority. Alternatively, information on drug use may not routinely be elicited or disclosed in the 
clinical context. As the potential for DDIs is highest between ritonavir-boosted PI regimens and EDDs, 
benzodiazepines, ketamine, and chemsex drugs, we highlight the importance of clinician awareness of 
patients’ use of these specific recreational drugs. National HIV treatment guidelines could benefit from 
inclusion of potential DDIs with specific recreational drugs and guidance on choice of regimen, dosage 
adjustment, monitoring, and provision of information to patients. There is a need for healthcare providers to 
maintain a non-judgmental attitude in discussing drug and alcohol use and DDIs, while offering support on ART 
adherence and safe drug use (including provision of harm reduction materials), or referral to club drug clinics. 
Community peer-led initiatives play a key role in producing literature about DDIs, however, further studies are 
needed to describe DDIs between ART and recreational drugs, particularly between PI/r and ketamine, GHB, 
and when used in conjunction with alcohol.   
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Table 1: Recreational drug use in the previous three months according to ART regimen (N=1167 MSM on 
ART) 
All HIV-diagnosed MSM on ART (N=1,167) 
Ritonavir or 
cobicistat boosted 
regimen (N=624) 
EFV or NVP 
regimen only 
(not PI/r) 
(N=523) 
All other regimens 
(N=20)▪ 
  N col % n col % n col % n col % 
Any recreational drug use  
 
  
  
   
 Yes  613 52.5 338 54.2 265 50.7 10 50.0 
No  554 47.5 286 45.8 258 49.3 10 50.0 
Polydrug use 
 
  
 
   
  1-2 drugs used 318 27.3 171 27.4 143 27.3 4 20.0 
3 or more drugs used  295 25.3 167 26.8 122 23.3 6 30.0 
Chemsex drug use* 
 
  
     
 Yes  184 15.8 104 16.7 79 15.1 1 5.0 
No 983 84.2 520 83.3 444 84.9 19 95.0 
Crystal methamphetamine 
 
  
     
 Yes  111 9.5 62 9.9 48 9.2 1 5.0 
No 1056 90.5 562 90.1 475 90.8 19 95.0 
GHB 
 
  
     
 Yes  118 10.1 67 10.7 50 9.6 1 5.0 
No 1049 89.9 557 89.3 473 90.4 19 95.0 
Mephedrone  
 
  
     
 Yes  75 6.4 42 6.7 32 6.1 1 5.0 
No 1092 93.6 582 93.3 491 93.9 19 95.0 
Ketamine  
 
  
     
 Yes  141 12.1 69 11.1 66 12.6 6 30.0 
No  1,026 87.9 555 88.9 457 87.4 14 70.0 
Erectile dysfunction drugs ◊ 
 
  
     
 Yes  259 22.2 151 24.2 103 19.7 5 25.0 
No  908 77.8 473 75.8 420 80.3 15 75.0 
Cocaine  
 
  
     
 Yes  256 21.9 136 21.8 115 22.0 5 25.0 
No 911 78.1 488 78.2 408 78.0 15 75.0 
MDMA  
 
  
     
 Yes 127 10.9 67 10.7 56 10.7 4 20.0 
No 1040 89.1 557 89.3 467 89.3 16 80.0 
Alcohol consumption ‡ 
 
  
     
 High 180 15.4 92 14.7 88 16.8 0 - 
None/moderate 987 84.6 532 85.3 435 83.2 20 100.0 
▪ Includes rilpivirine, raltegravir, dolutegravir, or maraviroc based regimens and emtricitabine/tenofovir/etravirine 
* Methamphetamine, GHB/GBL, or mephedrone 
◊ Sildenafil, tadalafil 
  
 
     ‡ Score ≥6 on modified WHO AUDIT-C questionnaire 
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